Cargando…
Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
BACKGROUND: Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-pr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603582/ https://www.ncbi.nlm.nih.gov/pubmed/34798808 http://dx.doi.org/10.1186/s12872-021-02358-y |
_version_ | 1784601794816507904 |
---|---|
author | Staszewsky, Lidia Meessen, Jennifer M. T. A. Novelli, Deborah Wienhues-Thelen, Ursula-Henrike Disertori, Marcello Maggioni, Aldo P. Masson, Serge Tognoni, Gianni Franzosi, Maria Grazia Lucci, Donata Latini, Roberto |
author_facet | Staszewsky, Lidia Meessen, Jennifer M. T. A. Novelli, Deborah Wienhues-Thelen, Ursula-Henrike Disertori, Marcello Maggioni, Aldo P. Masson, Serge Tognoni, Gianni Franzosi, Maria Grazia Lucci, Donata Latini, Roberto |
author_sort | Staszewsky, Lidia |
collection | PubMed |
description | BACKGROUND: Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-proBNP) in AF is still unknown. OBJECTIVES: To test how deglycosylated total NT-proBNP, NT-proBNP and a panel of biomarkers are associated with: (1) recurrent AF, (2) first hospitalization for CV reasons. METHODS: A total of 382 patients of the GISSI-AF trial in sinus rhythm with a history of AF, echocardiographic variables, total NT-proBNP, NT-proBNP and nine additional biomarkers [Total N-terminal pro-B type natriuretic peptide (Total NT proBNP), N-terminal pro-B type natriuretic peptide (NTproBNP), Angiopoietin 2 (Ang2), Bone morphogenic protein-10 (BMP10), Dickkopf-related protein-3 (DKK3), Endothelial cell specific molecule-1 (ESM1), Fatty acid-binding protein 3 (FABP3), Fibroblast growth factor 23 (FGF23), Growth differentiation factor-15 (GDF15), Insulin-like growth factor-binding protein-7 (IGFBP7) and Myosin binding protein C3 (MYPBC3)]. were assayed at baseline, 6 and 12 months under blind conditions in a laboratory at Roche Diagnostics, Penzberg, Germany. The associations between circulating biomarkers and AF at the 6- and 12-month visits, and their predictive value, were assessed in multivariable models with logistic regression analysis and Cox proportional hazards regression analysis. Biomarkers associations were modelled for 1SD increase in their level. RESULTS: Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for CV reasons. Total NT-proBNP, NT-proBNP, Ang2 and BMP10 showed the strongest associations with ongoing AF. Natriuretic peptides also predicted recurrent AF (total NT-proBNP: HR:1.19[1.04–1.36], p = 0.026; NT-proBNP: HR:1.19[1.06–1.35], p = 0.016; Ang2: HR:1.07[0.95–1.20], p = 0.283; BMP10: HR:1.09[0.96–1.25], p = 0.249) and CV hospitalization (total NT-proBNP: HR:1.57[1.29–1.90], p < 0.001 1.63], p = 0.097). CONCLUSIONS: The association of total NT-proBNP with the risk of AF first recurrence was similar to that of NT-proBNP, suggesting no influence of glycosylation. Analogous results were obtained for the risk of first hospitalization for CV reasons. Natriuretic peptides, Ang2 and BMP10 were associated with ongoing AF. Findings from the last two biomarkers point to a pathogenic role of cardiac extracellular matrix and cardiomyocyte growth in the myocardium of the right atrium and ventricle. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02358-y. |
format | Online Article Text |
id | pubmed-8603582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86035822021-11-19 Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation Staszewsky, Lidia Meessen, Jennifer M. T. A. Novelli, Deborah Wienhues-Thelen, Ursula-Henrike Disertori, Marcello Maggioni, Aldo P. Masson, Serge Tognoni, Gianni Franzosi, Maria Grazia Lucci, Donata Latini, Roberto BMC Cardiovasc Disord Research BACKGROUND: Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-proBNP) in AF is still unknown. OBJECTIVES: To test how deglycosylated total NT-proBNP, NT-proBNP and a panel of biomarkers are associated with: (1) recurrent AF, (2) first hospitalization for CV reasons. METHODS: A total of 382 patients of the GISSI-AF trial in sinus rhythm with a history of AF, echocardiographic variables, total NT-proBNP, NT-proBNP and nine additional biomarkers [Total N-terminal pro-B type natriuretic peptide (Total NT proBNP), N-terminal pro-B type natriuretic peptide (NTproBNP), Angiopoietin 2 (Ang2), Bone morphogenic protein-10 (BMP10), Dickkopf-related protein-3 (DKK3), Endothelial cell specific molecule-1 (ESM1), Fatty acid-binding protein 3 (FABP3), Fibroblast growth factor 23 (FGF23), Growth differentiation factor-15 (GDF15), Insulin-like growth factor-binding protein-7 (IGFBP7) and Myosin binding protein C3 (MYPBC3)]. were assayed at baseline, 6 and 12 months under blind conditions in a laboratory at Roche Diagnostics, Penzberg, Germany. The associations between circulating biomarkers and AF at the 6- and 12-month visits, and their predictive value, were assessed in multivariable models with logistic regression analysis and Cox proportional hazards regression analysis. Biomarkers associations were modelled for 1SD increase in their level. RESULTS: Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for CV reasons. Total NT-proBNP, NT-proBNP, Ang2 and BMP10 showed the strongest associations with ongoing AF. Natriuretic peptides also predicted recurrent AF (total NT-proBNP: HR:1.19[1.04–1.36], p = 0.026; NT-proBNP: HR:1.19[1.06–1.35], p = 0.016; Ang2: HR:1.07[0.95–1.20], p = 0.283; BMP10: HR:1.09[0.96–1.25], p = 0.249) and CV hospitalization (total NT-proBNP: HR:1.57[1.29–1.90], p < 0.001 1.63], p = 0.097). CONCLUSIONS: The association of total NT-proBNP with the risk of AF first recurrence was similar to that of NT-proBNP, suggesting no influence of glycosylation. Analogous results were obtained for the risk of first hospitalization for CV reasons. Natriuretic peptides, Ang2 and BMP10 were associated with ongoing AF. Findings from the last two biomarkers point to a pathogenic role of cardiac extracellular matrix and cardiomyocyte growth in the myocardium of the right atrium and ventricle. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02358-y. BioMed Central 2021-11-19 /pmc/articles/PMC8603582/ /pubmed/34798808 http://dx.doi.org/10.1186/s12872-021-02358-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Staszewsky, Lidia Meessen, Jennifer M. T. A. Novelli, Deborah Wienhues-Thelen, Ursula-Henrike Disertori, Marcello Maggioni, Aldo P. Masson, Serge Tognoni, Gianni Franzosi, Maria Grazia Lucci, Donata Latini, Roberto Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation |
title | Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation |
title_full | Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation |
title_fullStr | Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation |
title_full_unstemmed | Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation |
title_short | Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation |
title_sort | total nt-probnp, a novel biomarker related to recurrent atrial fibrillation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603582/ https://www.ncbi.nlm.nih.gov/pubmed/34798808 http://dx.doi.org/10.1186/s12872-021-02358-y |
work_keys_str_mv | AT staszewskylidia totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT meessenjennifermta totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT novellideborah totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT wienhuesthelenursulahenrike totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT disertorimarcello totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT maggionialdop totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT massonserge totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT tognonigianni totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT franzosimariagrazia totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT luccidonata totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation AT latiniroberto totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation |